The Drug Regulatory Authority of Pakistan (DRAP) is striving to create an environment that is conducive for developing the pharmaceutical sector of the country, said DRAP CEO Asim Rauf.
In a meeting with business community at the Lahore Chamber of Commerce and Industry (LCCI) on Monday, he stressed that the authority was working to steer ease of doing business to help Pakistan’s pharmaceutical sector to come on a par with the rest of the world.
“In order to achieve the goals set by Prime Minister Imran Khan, we have introduced the maximum automation system to ensure transparency and merit in all aspects,” he added.
Rauf pointed out that after the Covid-19 outbreak in Pakistan, DRAP increased its testing capacity substantially and contributed in every way from the availability of vaccines to raising awareness among the people.
Speaking on the occasion, LCCI President Mian Tariq Misbah recalled that DRAP had introduced a new format for drug registration (CTD), but the pharmaceutical industry opposed its implementation owing to the lengthy procedure and called for introducing an easy way for the registration of drugs.
He said that the yearly revision letters of many companies in relation to the Consumer Price Index (CPI) were pending and stressed that they should be released without any further delay.
He mentioned that the minutes of registration board meetings were not published timely, which should be uploaded on DRAP website within two weeks of the meeting.
Published in The Express Tribune, June 15h, 2021.
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ